NeuroOne Medical Technologies Corp.

How big is NeuroOne Medical Technologies Corp.?

As of Jun 18, NeuroOne Medical Technologies Corp. has a market capitalization of 32.38 million, with net sales of 8.76 million and a net profit loss of 6.60 million over the latest four quarters. Shareholder's funds are 0.82 million, and total assets amount to 5.37 million as of Sep 24.

As of Jun 18, NeuroOne Medical Technologies Corp. has a market capitalization of 32.38 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 8.76 million for the latest four quarters. During the same period, it experienced a net profit loss of 6.60 million.<BR><BR>As of Sep 24, the reporting period for the balance sheet shows shareholder's funds of 0.82 million and total assets of 5.37 million.

What does NeuroOne Medical Technologies Corp. do?

NeuroOne Medical Technologies Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $2 million as of March 2025, with a market cap of $32.38 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -626.73%.

Overview:<BR>NeuroOne Medical Technologies Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 32.38 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.08 <BR>Return on Equity: -626.73% <BR>Price to Book: 28.76<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold NeuroOne Medical Technologies Corp.?

Is NeuroOne Medical Technologies Corp. overvalued or undervalued?

As of December 22, 2022, NeuroOne Medical Technologies Corp. is considered a risky investment due to its high price-to-book ratio of 25.74, negative EV to EBITDA of -4.39, and extremely low return on equity of -626.73%, indicating poor financial health and underperformance compared to the S&P 500.

As of 22 December 2022, the valuation grade for NeuroOne Medical Technologies Corp. moved from does not qualify to risky. The company appears to be overvalued given its high price-to-book value of 25.74 and negative EV to EBITDA of -4.39, indicating significant challenges in generating earnings relative to its enterprise value. Additionally, the return on equity (ROE) is alarmingly low at -626.73%, reflecting poor profitability and financial health.<BR><BR>In comparison to its peers, NeuroOne's valuation ratios are concerning; for instance, LENSAR, Inc. has a worse EV to EBITDA of -12.34, while Singular Genomics Systems, Inc. shows a more favorable EV to EBITDA of 0.55. The stock's recent performance has lagged behind the S&P 500, with a year-to-date return of 8.96% compared to the S&P's 12.22%, suggesting that investors may be better served by looking elsewhere in the market.

Is NeuroOne Medical Technologies Corp. technically bullish or bearish?

As of September 8, 2025, NeuroOne Medical Technologies Corp. shows a mildly bullish trend supported by positive weekly and monthly MACD and Bollinger Bands, despite mixed signals from daily moving averages and underperformance over the past year compared to the S&P 500.

As of 8 September 2025, the technical trend for NeuroOne Medical Technologies Corp. has changed from sideways to mildly bullish. The weekly MACD and KST are both bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate bullish conditions on both weekly and monthly time frames. However, daily moving averages are mildly bearish, and there are no signals from the RSI or trends noted in Dow Theory. The stock has shown a 1-month return of 8.42%, outperforming the S&P 500's 2.33% return, but has underperformed over longer periods, including a 1-year return of 4.76% compared to the S&P 500's 17.14%. Overall, the current stance is mildly bullish, supported by several indicators, despite some mixed signals in shorter time frames.